Elevance Health: Undervalued Defensive Giant With Long-Term Upside

Elevance Health (ELV) is presented as an undervalued defensive investment, trading at a 41% discount to peers despite robust revenue growth and a 2.11% dividend yield. Although a recent selloff was driven by bottom-line contraction and lowered FY2025 EPS guidance, the company maintains strong profitability and low leverage amidst margin pressures from rising Medicaid and ACA costs. An analyst issues a "Buy" rating with a $400 FY2026 price target, implying 23% upside, citing market mispricing of ELV's resilience and growth potential.

Analysis

Elevance Health (ELV) presents a compelling, albeit conflicted, investment case defined by a significant valuation disconnect from its underlying operational strength. The company trades at a 41% discount to industry peers, a gap largely attributed to a recent selloff triggered by bottom-line contraction and lowered FY2025 EPS guidance. These headwinds are a direct result of margin pressures from rising Medicaid and ACA costs, a key risk factor for the managed care sector. Despite these near-term challenges, the fundamental picture remains robust, characterized by strong revenue growth, particularly in its Carelon segment, strong profitability, and low leverage. The company's defensive profile is further supported by a shareholder-friendly capital allocation strategy, which includes a 2.11% dividend yield. The analyst's 'Buy' thesis posits that the market is overly penalizing ELV for short-term margin issues and sector-wide pessimism, thereby mispricing its long-term growth and resilience, with a projected FY2026 price target of $400 implying a 23% upside.

Key Decisions for Investors

• Investors should consider if the 41% valuation discount to peers represents a sufficient margin of safety to initiate a position, weighing robust revenue growth against the lowered FY2025 earnings guidance.
• It is critical to monitor future earnings reports for any signs of margin stabilization, as continued pressure from Medicaid and ACA costs constitutes the primary risk to the investment thesis.
• The investment case is predicated on a long-term outlook, aligning with the FY2026 price target, which suggests that patience will be required for the market to potentially look past the current earnings headwinds.
• Factor in the 2.11% dividend yield as a source of return that could partially mitigate volatility while waiting for the valuation gap to potentially close.